Abstract 2388
Background
EV-201 (NCT03219333) is a single-arm, 2-cohort study of EV in mUC patients treated with prior CPI and platinum-containing chemotherapy (Cohort 1) or a CPI and no prior chemotherapy and are cisplatin-ineligible (Cohort 2). The confirmed ORR rate was 44%. Patient-reported outcome (PRO) measures were included in EV-201 as exploratory endpoints. Our objective was to explore the impact of EV on QoL in Cohort 1 of EV-201.
Methods
Two validated instruments were included (EORTC QLQ-C30 v3 and EQ-5D-3L). The 30-item EORTC QLQ-C30 measures functioning, symptoms, and financial impact with scores ranging from 0 to 100. The 5-item EQ-5D measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted to a score ranging from 0 to 1, with 0 representing death and 1 representing perfect health. The EQ-5D also records self-rated health status on a 0-100 visual analogue scale (VAS). Assessments were completed at baseline and start of each cycle.
Results
Of 125 subjects from Cohort 1, 120 (96%) received EV and completed both instruments at baseline. Across all cycles, >86% of subjects with available data at each cycle completed both instruments. QLQ-C30 domain scores, inclusive of general QoL, functioning, and symptom scores, remained stable over time. Some domains demonstrated trends toward improvement across the study period (e.g. emotional, role, and social functioning, as well as pain, fatigue, appetite loss, constipation, and diarrhea) (Table). EQ-5D utility and VAS scores also remained stable throughout the treatment period. Variability and small sample size limit definitive conclusions.Table:
921P Patient reported outcomes at baseline, cycle 5, and cycle 10
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Mean (SD) Scores | Baseline n = 120 | Cycle 5 n = 59 | Cycle 10 n = 12 |
---|---|---|---|
Global quality of life | 63.0 (20.8) | 65.4 (19.8) | 69.4 (25.0) |
Functional domains | |||
Physical functioning | 76.4 (20.8) | 78.9 (16.7) | 92.2 (8.4) |
Role functioning | 73.3 (27.8) | 74.3 (23.2) | 84.7 (11.1) |
Emotional functioning | 81.7 (18.4) | 85.3 (17.7) | 86.8 (11.5) |
Cognitive functioning | 85.3 (19.2) | 83.9 (18.8) | 93.1 (13.2) |
Social functioning | 73.5 (26.1) | 76.3 (25.7) | 86.1 (21.1) |
Symptom scales | |||
Fatigue | 35.3 (22.9) | 36.4† (21.1) | 17.6† (12.9) |
Nausea and vomiting | 9.0 (15.9) | 5.5† (13.0) | 1.4† (4.8) |
Dyspnoea | 16.9 (23.4) | 17.5† (27.5) | 13.9† (17.2) |
Insomnia | 27.2 (28.7) | 22.4† (22.8) | 11.1† (16.4) |
Appetite loss | 24.7 (30.1) | 23.6† (25.8) | 11.1† (25.9) |
Constipation | 24.4 (30.5) | 13.2† (20.7) | 8.3† (15.1) |
Diarrhea | 8.9 (18.2) | 6.8† (16.1) | 5.6† (13.0) |
Pain | 29.9 (28.7) | 22.3† (26.6) | 4.2† (7.5) |
Financial difficulties | 18.2 (30.0) | 19.2† (27.8) | 27.8† (27.8) |
EuroQol 5 dimension 3 level Questionnaire (EQ-5D-3L) Mean (SD) scores | |||
Visual analogue scale (VAS) | 66.9 (20.5) | 67.1 (20.8) | 78.4 (27.3) |
Utility score | 0.795 (0.163) | 0.809 (0.148) | 0.910 (0.102) |
Higher scores represent a positive effect except for symptom domains as marked with †, where higher scores represent greater symptom burden. SD – standard deviation.
Conclusions
Findings demonstrate that QoL is either maintained or improved for patients on treatment with EV, which complement the efficacy and safety results from EV-201 Cohort 1.
Clinical trial identification
NCT03219333.
Editorial acknowledgement
Lisa Bloudek of Curta, funded by Seattle Genetics. Shang-Ying Liang of Seattle Genetics provided statistical support and QC of results.
Legal entity responsible for the study
Seattle Genetics Inc.
Funding
Seattle Genetics, Inc. and Astellas Pharma, Inc.
Disclosure
B.A. McGregor: Advisory / Consultancy: Astellas Pharma Inc.; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Decibel Therapeutics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy: Janssen; Advisory / Consultancy: Nextar; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Calithera Biosciences. P.H. O’Donnell: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Shareholder / Stockholder / Stock options: Allergan; Shareholder / Stockholder / Stock options: PrescriptIQ; Honoraria (self), Honoraria (institution): Astellas Pharma Inc.; Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Genentech; Honoraria (self), Honoraria (institution): Harrison Consulting Group; Honoraria (self), Honoraria (institution): Inovio; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution), Non-remunerated activity/ies, Other Relationship: Janssen; Honoraria (self), Honoraria (institution): Kantar Health; Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Honoraria (institution): OncLive; Honoraria (self), Honoraria (institution): Parexel; Honoraria (self), Honoraria (institution): Quintiles; Research grant / Funding (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): Acerta; Non-remunerated activity/ies, Other Relationship: Advance Medical; Licensing / Royalties: Named as co-inventor on pending patent for a genomic prescribing system for medication prescribing. A. Balar: Advisory / Consultancy: Astellas Pharma Inc.; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Genentech; Advisory / Consultancy: Incyte; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Merck; Advisory / Consultancy: Pfizer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics. D.P. Petrylak: Advisory / Consultancy: Astellas Pharma Inc.; Research grant / Funding (self), Research grant / Funding (institution): Astellas Medivation; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bayer; Advisory / Consultancy: Bellicum Pharma; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Ferring; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Johnson&Johnson; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): MedImmune; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Tyme; Research grant / Funding (self), Research grant / Funding (institution): Agensys; Research grant / Funding (self), Research grant / Funding (institution): Clovis Onc; Research grant / Funding (self), Research grant / Funding (institution): Endocyte; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Lilly; Advisory / Consultancy: Medivation; Research grant / Funding (self), Research grant / Funding (institution): Genentech; Research grant / Funding (self), Research grant / Funding (institution): Innocrin Pharma; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Progenics; Research grant / Funding (self), Research grant / Funding (institution): Sotio. J.E. Rosenberg: Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Agensys; Honoraria (self), Honoraria (institution): AstraZeneca; Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy: Bayer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Inovo Pharmaceuticals; Advisory / Consultancy: Lilly; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Merck; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Seattle Genetics; Shareholder / Stockholder / Stock options: Illumina; Honoraria (self), Honoraria (institution): Medcape; Honoraria (self), Honoraria (institution): Peerview; Honoraria (self), Honoraria (institution): UpToDate; Honoraria (self), Honoraria (institution): Vindico; Licensing / Royalties: Predictor of Platinum sensitivity; Research grant / Funding (self), Research grant / Funding (institution): Incyte; Research grant / Funding (self), Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Oncogenex; Research grant / Funding (self), Research grant / Funding (institution): Viralytics. E. Yu: Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Churchill Pharma; Advisory / Consultancy, Research grant / Funding (institution): Dendreon; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: QED Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy: Tolmar; Advisory / Consultancy: Pharmacyclics; Research grant / Funding (institution): Agensys; Research grant / Funding (self): Daiichi Sankyo. D.I. Quinn: Full / Part-time employment: University of Southern California; Research grant / Funding (institution): Seattle Genetics; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Dendreon; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi. S.N. Shah: Full / Part-time employment: Astellas Pharma Inc. J. Pinelli: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. Z. Hepp: Shareholder / Stockholder / Stock options, Full / Part-time employment: Seattle Genetics. M. Galsky: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Genentech; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Dracen; Advisory / Consultancy: Dragonfly Therapeutics; Advisory / Consultancy: Astellas; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Janssen; Research grant / Funding (institution): Dendreon; Research grant / Funding (institution): Roche/Genentech.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract